Autopsy and Case Reports
Autopsy and Case Reports
Original Article

Study of EGFR mutations in head and neck squamous cell carcinomas

Gurpreet Kaur; Deepika Phogat; Venkatesan Manu

Downloads: 1
Views: 793


Introduction: Squamous carcinoma is the commonest malignancy of the head and neck region. It is associated with high morbidity and mortality. Epidermal growth factor receptor (EGFR) regulates downstream signaling pathways through its tyrosine kinase (TK) domains that play a role in cell proliferation and survival. EGFR mutations have been found to occur between exons 18 to 21 on chromosome 7. Limited studies are available on EGFR-TK mutations in the head and neck squamous cell carcinoma (HNSCC) globally. This study explores EGFR mutations in 30 HNSCC cases presenting to a tertiary care hospital over a period of two years.

Material and Methods: Fresh tumor tissue was collected from the resection specimens of cases of primary HNSCC. Cases with pre-operative therapy were not included. Parameters in the form of patients’ age, gender, smoking/tobacco intake, site of the lesion were recorded. Tumor parameters after histopathological examination were recorded in the form of TNM stage, tumor grade. DNA was extracted from fresh tissue of all the cases. EGFR Mutation Analysis Kit assay was used to detect mutations of the EGFR gene. PCR was run and results were analyzed.

Results: EGFR Mutations were found in 6.7%of the patients. There was no significant association of the EGFR Mutation with the studied parameters.

Conclusion: EGFR mutations are present in a subset of patients of HNSCC. Patients having these mutations may benefit from targeted therapy with tyrosine kinase inhibitors.


Biomarkers, Neoplasms, Genes, erbB-1, Genomics


1 Vigneswaran N, Williams M. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am. 2014;26(2):123-41. PMid:24794262.

2 Lala M, Chirovsky D, Cheng J, Mayawala K. Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): a systematic literature review. Oral Oncol. 2018;84:108-20. PMid:30115469.

3 Birkeland AC, Ludwig M, Meraj T, Brenner J, Prince M. The tip of the iceberg: clinical implications of genomic sequencing projects in head and neck cancer. Cancers (Basel). 2015;7(4):2094-109. PMid:26506389.

4 Solomon B, Young R, Rischin D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018;52(Pt 2):228-40. PMid:29355614.

5 Antonsson A, Neale R, Boros S, et al. Human papillomavirus status and p16INK4A expression in patients with mucosal squamous cell carcinoma of the head and neck in Queensland, Australia. Cancer Epidemiol. 2015;39(2):174-81. PMid:25677091.

6 Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials. 2013;34(34):8690-707. PMid:23953842.

7 Ohtsuka K, Ohnishi H, Furuyashiki G, et al. Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma. J Thorac Oncol. 2006;1(8):787-95. PMid:17409961.

8 Rawluk J, Waller C. Gefitinib. Recent Results Cancer Res. 2018(211):235-46.

9 Perisanidis C. Prevalence of EGFR tyrosine kinase domain mutations in head and neck squamous cell carcinoma: cohort study and systematic review. In Vivo. 2017;31(1):23-34. PMid:28064216.

10 Smilek P, Neuwirthova J, Jarkovsky J, et al. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. Neoplasma. 2012;59(05):508-15. PMid:22668015.

11 Nagalakshmi K, Jamil K, Pingali U, Reddy M, Attili S. Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC). Biomarkers. 2014;19(3):198-206. PMid:24712396.

12 Bahassi M, Li Y, Wise-Draper T, et al. A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer. Eur J Cancer. 2013;49(10):2345-55. PMid:23578570.

Submitted date:

Accepted date:

Publication date:

607872eca9539563225ab743 autopsy Articles
Links & Downloads

Autops Case Rep

Share this page
Page Sections